A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes

Vascular Health and Risk Management

Volumn 3, Issue 5, 2007, Pages 721-731

  Dorkhan, Mozhgan ^a   Frid, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Glimepiride; Pioglitazone; Sulfonylureas; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; BIGUANIDE DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; LIPID; METFORMIN; NICORANDIL; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE MODEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFE EXPECTANCY; LIVER; LIVER TOXICITY; MICROANGIOPATHY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOLYSIS; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKELETAL MUSCLE; WEIGHT GAIN;

ANIMALS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 36148960037     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Aljabri K, Kozak SE, Thompson DM. 2004. Addition of pioglitazone or bedtime insulin to maximal doses of sulfanylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med, 116:230-5.
2. Aronoff S, Rosenblatt S, Braithwaite S, et al. 2000. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care, 23:1605-11.
3. Ashcroft FM, Rorsman P. 1989. Electrophysiology of the pancreatic beta-cell. Prog Biophys Mol Biol, 54:87-143.
4. Balfour JA, Plosker GL. 1999. Rosiglitazone. Drugs, 57:921-30; discussion 931-2.
5. Belcher G, Lambert C, Edwards G, et al. 2005. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res Clin Pract, 70:53-62.
6. Belfort R, Harrison SA, Brown K, et al. 2006. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med, 355:2297-307.
7. Berhanu P, Kipnes MS, Khan MA, et al. 2006. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res, 3:39-44.
8. Betteridge DJ, Verges B. 2005. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia, 48:2477-81.
9. Bijlstra PJ, Lutterman JA, Russel FG, et al. 1996. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia, 39:1083-90.
10. Boyle PJ, King AB, Olansky L, et al. 2002. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther, 24:378-96.
11. Caldwell SH, Hespenheide EE, Redick JA, et al. 2001. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol, 96:519-25.
12. Campbell RK. 1998. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother, 32:1044-52.
13. Charbonnel B, Schernthaner G, Brunetti P, et al. 2005. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia, 48:1093-104.
14. Dahlem YA, Horn TF, Buntinas L, et al. 2004. The human mitochondrial KATP channel is modulated by calcium and nitric oxide: a patch-clamp approach. Biochim Biophys Acta, 1656:46-56.
15. Danchin N, Charpentier G, Ledru F, et al. 2005. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry. Diabetes Metab Res Rev, 21:143-9.
16. Davidson JA, Perez A, Zhang J. 2006. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes Obes Metab, 8:164-74.
17. Derosa G, Cicero AF, D'Angelo A, et al. 2006. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein a, and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther, 28:679-88.
18. Derosa G, Cicero AF, Dangelo A, et al. 2005a. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res, 28:917-24.
19. Derosa G, Cicero AF, Gaddi A, et al. 2005b. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract, 69:5-13.
20. Dills DG, Schneider J. 1996. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/ Glyburide Research Group. Horm Metab Res, 28:426-9.
21. Dorkhan M, Magnusson M, Frid A, et al. 2006. Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes. J Intern Med, 260:125-33.
22. Dormandy JA, Charbonnel B, Eckland DJ, et al. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study PROspective pioglitAzone Clinical Trial In macroVascular Events: a randomised controlled trial. Lancet, 366:1279-89.
23. Draeger KE, Wernicke-Panten K, Lomp HJ, et al. 1996. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride Amaryl.: a double-blind comparison with glibenclamide. Horm Metab Res, 28:419-25.
24. Dubois M, Pattou F, Kerr-Conte J, et al. 2000. Expression of peroxisome proliferator-activated receptor gamma PPARgamma, in normal human pancreatic islet cells. Diabetologia, 43:1165-9.
25. Duez H, Chao YS, Hernandez M, et al. 2002. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem, 277:48051-7.
26. Einhorn D, Rendell M, Rosenzweig J, et al. 2000. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther, 22:1395-409.
27. Eliasson L, Renstrom E, Ammala C, et al. 1996. PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cells. Science, 271:813-5.
28. Feinglos MN, Bethel MA. 1998. Treatment of type 2 diabetes mellitus. Med Clin North Am, 82:757-90.
29. Forman BM, Tontonoz P, Chen J, et al. 1995. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell, 83:803-12.
30. Forst T, Hohberg C, Fuellert SD, et al. 2005a. Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. Horm Metab Res, 37:521-7.
31. Forst T, Lubben G, Hohberg C, et al. 2005b. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation, 12:543-50.
32. Fukuen S, Iwaki M, Yasui A, et al. 2005. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem, 280:23653-9.
33. Fullert S, Schneider F, Haak E, et al. 2002. Effects of pioglitazone in non-diabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab, 87:5503-6.
34. Geisen K, Vegh A, Krause E, et al. 1996. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res, 28:496-507.
35. Gerber P, Lubben G, Heusler S, et al. 2003. Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus. Curr Med Res Opin, 19:532-9.
36. Gerstein HC, Yusuf S, Bosch J, et al. 2006. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet, 368:1096-105.
37. Ghosh S, Standen NB, Galinianes M. 2001. Failure to precondition pathological human myocardium. J Am Coll Cardiol, 37:711-8.
38. Gillies PS, Dunn CJ. 2000. Pioglitazone. Drugs, 60:333-43; discussion 344-5.
39. Goldberg RB, Kendall DM, Deeg MA, et al. 2005. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care, 28:1547-54.
40. Gosset P, Charbonnier AS, Delerive P, et al. 2001. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol, 31:2857-65.
41. Hanefeld M, Brunetti P, Schernthaner GH, et al. 2004. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care, 27:141-7.
42. Hellman B, Sehlin J, Taljedal IB. 1984. Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cell-rich pancreatic islets. Acta Endocrinol Copenh, 105:385-90.
43. Henry RR. 1997. Thiazolidinediones. Endocrinol Metab Clin North Am, 26:553-73.
44. Herz M, Johns D, Reviriego J, et al. 2003. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther, 25:1074-95.
45. Inukai K, Watanabe M, Nakashima Y, et al. 2005. Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes. Biochem Riophys Res Commun, 328:484-90.
46. Inzucchi SE. 2002. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA, 287:360-72.
47. IRIS. 2007. The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight. Diabetes, Obesity and Metabolism, 9:132-3.
48. Jain R, Osei K, Kupfer S, et al. 2006. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy, 26:1388-95.
49. Jernberg T, James S, Lindahl B, et al. 2004. Natriuretic peptides in unstable coronary artery disease. Eur Heart J, 25:1486-93.
50. Kahn SE, Haffner SM, Heise MA, et al. 2006. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med, 355:2427-43.
51. Kanatani Y, Usui I, Ishizuka K, et al. 2007. Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes, 56:795-803.
52. Karam JH, Matin SB, Forsham PH. 1975. Antidiabetic drugs after the University Group Diabetes Program UGDP. Annu Rev Pharmacol, 15:351-66.
53. Karthikeyan VJ, Lip G. Y. 2007. N-terminal pro-brain natriuretic peptide and coronary artery disease. Eur J Clin Invest, 37:1-7.
54. Kawamori R, Matsuhisa M, Kinoshita J, et al. 1998. Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. Diabetes Res Clin Pract, 41:35-43.
55. Khan M, Xu Y, Edwards G, et al. 2004. Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies. Int J Clin Pract, 58:907-12.
56. Kipnes MS, Krosnick A, Rendell, MS., et al. 2001. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med, 111:10-7.
57. Klepzig H, Kober G, Matter C, et al. 1999. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibericlamide. Eur Heart J, 20:439-46.
58. Kramer W, Muller G, Girbig F, et al. 1994. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride. Biochim Biophys Acta, 1191:278-90.
59. Langenfeld MR, Forst T, Hobberg C, et al. 2005. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation, 111:2525-31.
60. Lee TM, Chou TF. 2003. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab, 88:531-7.
61. Lehmann JM, Moore LB, Smith-Oliver TA, et al. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma PPAR gamma. J Biol Chem, 270:12953-6.
62. Lehtihet M, Welsh N, Berggren PO, et al. 2003. Glibenclamide inhibits islet carnitine palmitoyltransferase 1 activity, leading to PKC-dependent insulin exocytosis. Am J Physiol Endocrinol Metab, 285:E438-46.
63. Lemberger T, Desvergne B, Wahli W. 1996. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol, 12:335-63.
64. Luis Bautista J, Bugos C., Dirnberger G, et al. 2003. Efficacy and safety profile of glimepiride in Mexican American patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther, 25:194-209.
65. Martens FM, Rabelink TJ, op't Roodt J, et al. 2006. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J, 27:1605-9.
66. Martens FM, Visseren FL, de Koning EJ, et al. 2005. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol, 46:773-8.
67. Marx N, Mach F, Sauty A, et al. 2000. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol, 164:6503-8.
68. Marx N, Wohrle J, Nusser T, et al. 2005. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation, 112:2792-8.
69. Mattoo V, Eckland D, Widel M, et al. 2005. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther, 27:554-67.
70. Mazzone T, Meyer PM, Feinstein S, et al. 2006. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA, 296:2572-81.
71. Miyazaki Y, Glass L, Triplitt C, et al. 2001a. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia, 44:2210-9.
72. Miyazaki Y, Mahankali A, Matsuda M, et al. 2001b. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care, 24:710-9.
73. Miyazaki Y, Mahankali A, Matsuda M, et al. 2002a. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab, 87:2784-91.
74. Miyazaki Y, Mahankali A, Wajcberg E, et al. 2004. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab, 89:4312-9.
75. Miyazaki Y, Matsuda, M, DeFronzo, RA. 2002b. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care, 25:517-23.
76. Mocanu MM, Maddock, HL, Baxter, GF, et al. 2001. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation, 103:3111-6.
77. Nakamura T, Matsuda T, Kawagoe Y, et al. 2004. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism, 53:1382-6.
78. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. 2003. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology, 38:1008-17.
79. Nichols CG, Lederer WJ. 1991. Adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Am J Physiol, 261:H1675-86.
80. Nishio K, Sakurai M, Kusuyama T, et al. 2006. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care, 29:101-6.
81. Nolan JJ, Ludvik B, Beerdsen P, et al. 1994. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med, 331:1188-93.
82. Panzram G. 1987. Mortality and survival in type 2 non-insulin-dependent, diabetes mellitus. Diabetologia, 30:123-31.
83. Pavo I, Jermendy G, Varkonyi TT, et al. 2003. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab, 88:1637-45.
84. Perez A, Khan M, Johnson T, et al. 2004. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diab Vasc Dis Res, 1:44-50.
85. Pfutzner A, Hohberg C, Lubben G, et al. 2005a. Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm Metab Res, 37:510-5.
86. Pfutzner A, Marx N, Lubben G, et al. 2005b. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol, 45:1925-31.
87. 1c: a meta-analysis of published randomized clinical trials. Curr Med Res Opin, 22:2267-78.
88. Proks P, Reimann F, Green N, et al. 2002. Sulfonylurea stimulation of insulin secretion. Diabetes, 51(Suppl 3):S368-76.
89. Prout TE. 1971. A prospective view of the treatment of adult-onset diabetes with special reference to the University Group Diabetes Program and oral hypoglycemic agents. Med Clin North Am, 55:1065-75.
90. Quast U, Stephan D, Bieger S, et al. 2004. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes, 53(Suppl 3):S156-64.
91. Quayle JM, Nelson MT, Standen NB. 1997. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev, 77:1165-232.
92. Rasouli N, Raue U, Miles LM, et al. 2005. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab, 288: E930-4.
93. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. 2006. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev, CD006060.
94. Riveline JP, Danchin N, Ledru F, et al. 2003. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab, 29:207-22.
95. Rosenblatt S, Miskin B, Glazer NB, et al. 2001. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis, 12:413-23.
96. Rosenstock J, Einhorn D, Hershon K, et al. 2002. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract, 56:251-7.
97. Rosenstock J, Samols E, Muchmore DB, et al. 1996. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care, 19:1194-9.
98. Rubins HB, Robins SJ, Collins D, et al. 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med, 341:410-8.
99. Saltiel AR, Olefsky JM. 1996. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes, 45:1661-9.
100. Sanyal AJ, Mofrad PS, Contos MJ, et al. 2004. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol, 2:1107-15.
101. Sarafidis PA, Bakris GL. 2006. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int, 70:1223-33.
102. Sato T, Nishida H, Miyazaki M, Nakaya, H. 2006. Effects of sulfonylureas on mitochondrial ATP-sensitive K+ channels in cardiac myocytes: implications for sulfonylurea controversy. Diabetes Metab Res Rev, 22:341-7.
103. Scherbaum WA, Goke B. 2002. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res, 34:589-95.
104. Schernthaner G, Grimaldi A, Di Mario U, et al. 2004a. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest, 34:535-42.
105. Schernthaner G, Matthews DR, Charbonnel B, et al. 2004b. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab, 89:6068-76.
106. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. 2006. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab, 91:3349-54.
107. Shadid S, Jensen MD. 2003. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care, 26:3148-52.
108. Smith SR, De Jonge L, Volaufova J, et al. 2005. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism, 54:24-32.
109. Stamler J, Vaccaro O, Neaton JD, et al. 1993. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 16:434-44.
110. Stratton IM, Adler AI, Neil HA, et al. R. 2000. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes UKPDS 35.: prospective observational study. BMJ, 321:405-12.
111. Takagi T, Yamamuro A, Tamita K, et al. 2003. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J, 146:E5.
112. Tan M, Johns D, Gonzalez Galvez G, et al. 2004a. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. Clin Ther, 26:680-93.
113. Tan MH, Johns D, Strand J, et al. 2004b. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Diabet Med, 21:859-66.
114. Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al. 2004. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes, 53:2169-76.
115. Tran MT, Navar MD, Davidson MB. 2006. Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes. Diabetes Care, 29:1395-6.
116. UKPDS. 1998a. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes UKPDS 34. UK Prospective Diabetes Study UKPDS. Group. Lancet, 352:854-65.
117. UKPDS. 1998b. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS 33. UK Prospective Diabetes Study UKPDS. Group. Lancet, 352:837-53.
118. Wallace TM, Levy JC, Matthews DR. 2004. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med, 21:568-76.
119. Wilcox R, Bousser MG, Betteridge DJ, et al. 2007. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive PROspective pioglitAzone Clinical Trial In macroVascular Events 04. Stroke, 38:865-73.
120. Willson TM, Lambert MH, Kliewer SA. 2001. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem, 70:341-67.
121. Winkler K, Konrad T, Fullert S, et al. 2003. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care, 26:2588-94.
122. Yamada K, Ji A Yuan H, et al. 2001. Protective role of ATP-sensitive potassium channels in hypoxia-induced generalized seizure. Science, 292:1543-6.
123. Yki-Jarvinen H. 2005. The PROactive study: some answers, many questions. Lancet, 366:1241-2.
124. Zhang F, Sjoholm K, Zhang Q. 2006. Pioglitazone acutely influences glucose-sensitive insulin secretion in normal and diabetic human islets. Biochem Biophys Res Commun, 351:750-5.
125. Zingman LV, Hodgson DM, Bast PH, et al. 2002. Kir6.2 is required for adaptation to stress. Proc Natl Acad Sci USA, 99:13278-83.